Verastem(VSTM) - 2022 Q1 - Quarterly Report

Financial Performance - The company reported a net loss of $17.0 million for the three months ended March 31, 2022, compared to a net loss of $15.0 million for the same period in 2021, indicating a year-over-year increase in losses of approximately 13.3%[108] - Total revenue for the three months ended March 31, 2022, was $2.6 million, a 158% increase from $1.0 million in the same period of 2021[116] - Revenue from the sale of COPIKTRA license and related assets was $2.6 million in the 2022 Period, compared to $0.9 million in the 2021 Period, representing a 205% increase[116] - Net loss for the three months ended March 31, 2022, was $16.96 million, a 13% increase from a net loss of $15.03 million in the same period of 2021[116] - Total operating expenses rose by 30% to $19.6 million in the 2022 Period from $15.1 million in the 2021 Period[116] - Research and development expenses increased by 53% to $13.6 million in the 2022 Period from $8.9 million in the 2021 Period, driven by costs associated with clinical trials[118] Cash and Financing - As of March 31, 2022, the company had an accumulated deficit of $680.7 million and cash, cash equivalents, and investments totaling $106.3 million, which are expected to fund operations for at least the next 12 months[108] - Cash, cash equivalents, and investments as of March 31, 2022, totaled $106.3 million[125] - Cash used in operating activities for the 2022 Period was $19.3 million, similar to $19.3 million in the 2021 Period[127] - Cash provided by financing activities for the 2022 Period was $25.5 million, compared to cash used of $0.6 million in the 2021 Period[127] - The company entered into a loan agreement with Oxford for up to $150 million, with an initial term loan of $25 million funded at closing[131] - The company borrowed $25.0 million under a Loan Agreement, with interest rates subject to fluctuations based on the one-month CME Secured Overnight Financing Rate plus 7.37%[168] - The company expects to continue incurring significant expenses and operating losses while funding its obligations for at least the next twelve months[158] - The company anticipates financing its cash needs through equity offerings, debt financings, collaborations, and milestone payments[163] Product Development - The company is focused on advancing its lead product candidates, VS-6766 and defactinib, which are being investigated for various solid tumors, including low-grade serous ovarian cancer and KRAS mutant non-small cell lung cancer[92][93] - VS-6766 has received breakthrough designation from the FDA for the treatment of all patients with recurrent low-grade serous ovarian cancer, regardless of KRAS status, after one or more prior lines of therapy[97] - The combination of VS-6766 and defactinib is being evaluated in the FRAME study for patients with recurrent low-grade serous ovarian cancer and KRAS mutant tumors, with registration-directed trials RAMP 201 and 202 initiated based on preliminary results[99][100] - The company entered into a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRAS in a Phase 1/2 trial[101] - Defactinib has received orphan drug designation in ovarian cancer in the U.S., EU, and Australia, highlighting its potential in treating this indication[96] Operational Challenges - The ongoing COVID-19 pandemic has impacted clinical trial operations, with delays in startup activities and limits on new trials at some sites, which may affect the company's timelines[110] - The company has financed its operations primarily through public offerings, collaborations, and loans, indicating a reliance on external funding sources for ongoing development[105][109] Licensing and Agreements - The company entered into a license agreement with Secura, receiving an upfront payment of $70.0 million and potential regulatory milestone payments up to $45.0 million[149] - Secura is obligated to pay sales milestone payments of up to $50.0 million based on COPIKTRA's worldwide net sales exceeding $100.0 million, $200.0 million, and $300.0 million[149] - The company recognized $2.6 million in revenue from the sale of COPIKTRA license and related assets during the 2022 Period, primarily from a regulatory milestone[152] - The company has entered into a license agreement with Chugai for the development and commercialization of products containing VS-6766, with an upfront payment of $3.0 million[153]